Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 27, Number 12—December 2021
Research Letter

Breakthrough Infections of E484K-Harboring SARS-CoV-2 Delta Variant, Lombardy, Italy

Andreina BajComments to Author , Federica Novazzi, Renee Pasciuta, Angelo Genoni, Francesca Drago Ferrante, Marilena Valli, Michele Partenope, Rosalia Tripiciano, Andrea Ciserchia, Giuseppe Catanoso, Daniele Focosi, and Fabrizio Maggi
Author affiliations: ASST SetteLaghi, Varese, Italy (A. Baj, F. Novazzi, R. Pasciuta, F. Drago Ferrante, F. Maggi); University of Insubria, Varese (A. Baj, A. Genoni, F. Maggi); St. Anna Hospital, Como, Italy (M. Valli, M. Partenope); ATS Insubria, Varese (R. Tripiciano, A. Ciserchia, G. Catanoso); Pisa University Hospital, Pisa, Italy (D. Focosi)

Suggested citation for this article

Abstract

The Delta variant of concern of severe acute respiratory syndrome coronavirus 2 is dominant worldwide. We report a case cluster caused by Delta sublineage B.1.617.2 harboring the mutation E484K in Italy during July 11–July 29, 2021. This mutation appears to affect immune response and vaccine efficacy; monitoring its appearance is urgent.

Since the beginning of 2021, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant originally described in India has become the predominant circulating variant of the coronavirus disease pandemic. This variant of concern (VOC) was renamed Delta by the World Health Organization and consists to date of 5 different sublineages (B.1.617.2, AY.1, AY.2, AY.3, and AY.3.1, according to PANGOLIN phylogeny) that share T478K and L452R as the main mutations of concern (MOCs) within the spike protein. B.1.617.2 (also known as VUI-21APR-02) is by far the most represented Delta sublineage. None of the 5 sublineages are to date characterized by the occurrence of the other MOC E484K, which causes resistance to monoclonal antibodies and reduced vaccine efficacy. However, given the widespread convergent evolution of the spike protein observed across clades, the occurrence of MOC E484K and its widespread circulation is largely expected. A clade simultaneously harboring all such MOCs is likely to be of extreme concern because of theoretical increased immune escape. We report a cluster of B.1.617.2 and E484K occurring in Lombardy, Italy. All cases were first tested by real-time reverse transcription PCR and, if positive, sequenced as previously reported (1).

On July 11, 2021, a 41-year-old man from a small village in northern Lombardy (vaccinated with BNT162b2 [Pfizer-BioNTech, https://www.pfizer.com] on June 12 and July 12) began experiencing cough, fever, and malaise; a nasopharyngeal swab specimen tested positive on July 14 by the SARS-CoV-2 Variants Elite MGB Kit (EliTech Group, https://www.elitechgroup.com); cycle threshold (Ct) was 21 for open reading frame (ORF) 1ab gene and 21 for the nucleocapsid (N) gene. He fully recovered without need for hospital admission; whole-genome sequencing confirmed B.1.617.2 that harbored E484K. His 80-year-old mother (vaccinated with mRNA-1273 [Moderna, https://www.modernatx.com] on April 9 and May 7) experienced fatigue, headache, myalgia, and dyspnea beginning July 17 and tested positive on July 24 (Ct 22 for ORF1ab gene and Ct 21 for N gene). She likely further infected (while playing cards) a 77-year-old man (vaccinated with BNT162b2 on April 26 and May 17) who began experiencing fever July 21 and tested positive on July 23 (Ct 20 for ORF1ab gene and Ct 19 for N gene) and an 83-year-old woman (vaccinated with BNT162b2 on April 3 and April 24) who experienced fever, fatigue, ageusia, and anosmia beginning July 21 and tested positive July 24 (Ct 18 for both genes). None required hospital admission. An unrelated patient from the same village, an 81-year-old woman (vaccinated with mRNA-1273 on May 7 and June 9), experienced dyspnea, fever, myalgia, and fatigue beginning July 24. On July 29, she tested positive for SARS-CoV-2 RNA (Ct 23 for ORF1ab gene and Ct 21 for N gene), and she was admitted to the hospital. All sequences obtained in this study have been deposited into GISAID (https://www.gisaid.org; accession nos. EPI_ISL_3462078, EPI_ISL_3462074, EPI_ISL_3462072, EPI_ISL_346208).

E484K is the hallmark MOC of VOCs Beta and Gamma, in addition to having been reported in a minor sublineage of VOC Alpha, in variants of interest Eta and Iota, and at frequencies >50% in 38 more strains. E484K causes resistance to many class 2 RBD-directed antibodies (2), including bamlanivimab (3). The most potent mRNA vaccine–elicited monoclonal antibodies were >10-fold less effective against pseudotyped viruses carrying the E484K mutation (Z. Wang et al., unpub. data, https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2). As of August 12, 2021, GISAID reported E484K in 52 of 408,781 B.1.617.2 sequences, 2 of 549 AY.1 sequences, and 32 of 19,996 AY.3 (Delta) sequences; none of these reports were in Italy. E484K has been additionally reported in 1 of 6,011 B.1.617.1 (Kappa variant) sequences (4).

Nasopharyngeal swab specimens positive for the Delta variant have ≈4-fold higher viral loads than non-VOC or Alpha variants (C. von Wintersdorff et al., unpub. data, https://www.researchsquare.com/article/rs-762916/v1) and a shorter incubation time of 4 days (B. Li et al., unpub. data, https://www.medrxiv.org/content/10.1101/2021.07.07.21260122v1). It is resistant to REGN10933 (T. Tada et al., unpub. data, https://www.biorxiv.org/content/10.1101/2021.07.19.452771v3) and bamlanivimab (M. Hoffman et al., unpub. data, https://www.biorxiv.org/content/10.1101/2021.05.04.442663v1; P. Arora et al., unpub. data, https://www.biorxiv.org/content/10.1101/2021.06.23.449568v1), whereas neutralization by antibodies derived from cyclic citrullinated peptide, BNT162b2, mRNA-1273, and Ad26.COV2.S are reduced by 3–5-fold (T. Tada et al., unpub. data).

E484K mutation represents a critical evolutionary event that leads to immune escape, although its consequences on viral fitness are unclear. Surveillance by genome sequencing should be maintained (T. Farinholt et al., unpub. data, https://www.medrxiv.org/content/10.1101/2021.06.28.21258780v4).

Dr. Baj is a medical research scientist at University of Insubria, Varese, Italy. Her research interests include persistent and emerging viral infections.

Top

References

  1. Baj  A, Novazzi  F, Ferrante  FD, Genoni  A, Cassani  G, Prestia  M, et al. Introduction of SARS-COV-2 C.37 (WHO VOI lambda) from Peru to Italy. J Med Virol. 2021;•••:jmv.27235; Epub ahead of print. DOIPubMedGoogle Scholar
  2. Greaney  AJ, Starr  TN, Barnes  CO, Weisblum  Y, Schmidt  F, Caskey  M, et al. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat Commun. 2021;12:4196. DOIPubMedGoogle Scholar
  3. Starr  TN, Greaney  AJ, Dingens  AS, Bloom  JD. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. 2021;2:100255. DOIPubMedGoogle Scholar
  4. Latif  AA, Mullen  JL, Alkuzweny  M, Tsueng  G, Cano  M, Haag  E, et al. S:E484K mutation report. 2021 [cited 2021 Aug 12]. https://outbreak.info/situation-reports?pango&muts=S%3AE484K

Top

Suggested citation for this article: Baj A, Novazzi F, Pasciuta R, Genoni A, Drago Ferrante F, Valli M, et al. Breakthrough infections of E484K-harboring SARS-CoV-2 Delta variant, Lombardy, Italy. Emerg Infect Dis. 2021 Dec [date cited]. https://doi.org/10.3201/eid2712.211792

DOI: 10.3201/eid2712.211792

Original Publication Date: September 09, 2021

Table of Contents – Volume 27, Number 12—December 2021

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Dr.ssa Andreina Baj, Dipartimento di Medicina e Chirurgia, Universita’ degli Studi dell’Insubria, Laboratorio di Microbiologia Medica, Viale Borri 57, Varese, Italy

Send To

10000 character(s) remaining.

Top

Page created: September 02, 2021
Page updated: September 09, 2021
Page reviewed: September 09, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external